On April 24, 2026, Colombia launched a nationwide vaccination campaign targeting measles and yellow fever, opening 80 immunization points in Medellín alone as part of a broader effort to protect over 140,000 individuals amid rising regional transmission risks. The initiative, led by Colombia’s Ministry of Health and Social Protection, responds to confirmed outbreaks in neighboring countries and declining vaccination coverage in vulnerable populations, aiming to restore herd immunity through accessible, free-of-charge immunization services in urban and rural health centers.
In Plain English: The Clinical Takeaway
- Measles and yellow fever vaccines are safe, highly effective, and provide long-lasting protection after one or two doses.
- Vaccination prevents outbreaks by stopping virus spread, especially in communities with low immunization rates.
- Even if you sense healthy, getting vaccinated protects vulnerable people like infants, pregnant women, and those with weakened immune systems.
Understanding the Threat: Measles and Yellow Fever in 2026
Measles, caused by the measles morbillivirus, is one of the most contagious pathogens known to humans, spreading via respiratory droplets when an infected person coughs or sneezes. The virus initially infects the respiratory tract before disseminating through the bloodstream, leading to characteristic symptoms including high fever, cough, coryza, conjunctivitis, and a maculopapular rash. Complications such as pneumonia, encephalitis, and subacute sclerosing panencephalitis (SSPE) can occur, particularly in malnourished children and immunocompromised individuals. According to the World Health Organization (WHO), global measles cases increased by 18% in 2025 compared to the previous year, with over 9 million infections and 136,000 deaths reported, largely due to gaps in immunization coverage during and after the COVID-19 pandemic.
Yellow fever, caused by a flavivirus transmitted primarily by Aedes aegypti and Haemagogus mosquitoes, presents with sudden onset of fever, chills, severe headache, back pain, nausea, and vomiting. In approximately 15% of cases, the disease progresses to a toxic phase marked by jaundice, hemorrhagic manifestations, and multi-organ failure, with a case fatality rate of 20–50% in severe instances. Endemic in tropical regions of Africa and South America, yellow fever remains a significant public health concern, with the Pan American Health Organization (PAHO) reporting localized outbreaks in Brazil, Peru, and Bolivia in early 2026, raising concerns about cross-border transmission into Colombia.
How the Vaccines Work: Mechanism of Action and Immune Response
The measles vaccine, typically administered as part of the measles-mumps-rubella (MMR) trivalent vaccine, contains a live-attenuated strain of the virus. Upon subcutaneous injection, the weakened virus replicates minimally in the body, triggering a robust adaptive immune response without causing disease. This activates both humoral immunity — where B cells produce neutralizing antibodies targeting the viral hemagglutinin protein — and cell-mediated immunity, involving CD8+ T cells that eliminate infected cells. Protective immunity develops within 2–3 weeks after vaccination and is considered lifelong in over 97% of recipients following two doses.
The yellow fever vaccine, such as the 17D strain used in Colombia’s campaign, is also a live-attenuated vaccine. It works by infecting dendritic cells and macrophages at the injection site, leading to antigen presentation and the generation of neutralizing antibodies against the viral envelope (E) protein. A single dose confers protective immunity in 80–100% of recipients within 10 days and 99% within 30 days, with evidence suggesting durability of protection for at least 30–35 years, potentially for life. The vaccine does not contain thimerosal or adjuvants and is produced in embryonated chicken eggs under strict biosafety protocols.
Geo-Epidemiological Bridging: Colombia’s Response in Regional Context
Colombia’s national vaccination campaign aligns with WHO’s Immunization Agenda 2030 and PAHO’s regional strategy to eliminate measles and prevent yellow fever reurbanization. Unlike the U.S. FDA or Europe’s EMA, which regulate vaccines through centralized agencies, Colombia’s National Institute for Food and Drug Surveillance (INVIMA) oversees vaccine approval, lot release, and post-marketing surveillance in coordination with the Ministry of Health. The campaign leverages Colombia’s extensive primary care network, including Unidades Básicas de Salud (UBS) and Centros de Salud, to deliver vaccines door-to-door in underserved barrios and via mobile units in remote municipalities such as Quibdó, Leticia, and Puerto Carreño.
This effort is particularly critical in the Amazonas and Putumayo departments, where indigenous communities face heightened risk due to limited healthcare access and increased exposure to sylvatic (jungle) yellow fever cycles. By integrating traditional leaders and community health workers (promotores de salud), the campaign aims to improve vaccine acceptance and overcome geographic and cultural barriers. Similar strategies have been employed successfully in Brazil’s Amazon basin during yellow fever outbreaks, where ring vaccination and targeted outreach reduced transmission by over 60% within six months.
Funding, Partnerships, and Scientific Integrity
The 2026 national measles and yellow fever vaccination campaign in Colombia is primarily funded through the General System of Participations (Sistema General de Participaciones, SGP), with supplementary support from the Pan American Health Organization’s Revolving Fund for Vaccine Procurement and Gavi, the Vaccine Alliance. The Revolving Fund ensures equitable access to pre-qualified vaccines at affordable prices for participating countries, including Colombia, by aggregating demand and negotiating long-term contracts with manufacturers such as Serum Institute of India (for measles-containing vaccines) and Sanofi Pasteur (for the yellow fever vaccine YF-VAX).
All vaccines used in the campaign have undergone rigorous evaluation by WHO’s Prequalification Team and are listed on the WHO Emergency Use Listing (EU) or prequalified for use in immunization programs. Independent safety monitoring is conducted through Colombia’s National Pharmacovigilance System, which tracks adverse events following immunization (AEFI) in real time. No serious safety concerns have been linked to the MMR or yellow fever vaccines in Colombia’s recent campaigns, with transient mild-to-moderate reactions such as low-grade fever, soreness at injection site, or transient rash occurring in less than 10% of recipients and resolving spontaneously.
Contraindications & When to Consult a Doctor
Even as the measles and yellow fever vaccines are safe for the vast majority of the population, certain individuals should not receive them or should consult a healthcare provider beforehand. Contraindications for the MMR vaccine include a history of severe allergic reaction (anaphylaxis) to a prior dose or to any component such as gelatin or neomycin, known severe immunodeficiency (e.g., from hematologic malignancies, congenital immunodeficiencies, or high-dose immunosuppressive therapy), and pregnancy. Individuals with moderate to severe acute illness should delay vaccination until recovery.
For the yellow fever vaccine, additional contraindications include thymus disorders associated with abnormal immune cell function (such as myasthenia gravis or thymoma), hypersensitivity to egg proteins, and infants under 6 months of age. Adults aged 60 years and older have a slightly increased risk of rare serious adverse events like yellow fever vaccine-associated viscerotropic disease (YEL-AVD) or neurotropic disease (YEL-AND), though the absolute risk remains low (approximately 0.25 to 0.4 cases per 100,000 doses). Travelers to endemic areas, pregnant women during outbreaks, and infants aged 6–8 months may receive the vaccine under medical supervision when benefits outweigh risks.
Seek immediate medical attention if, after vaccination, you experience difficulty breathing, swelling of the face or lips, rapid heartbeat, dizziness, or high fever lasting more than 48 hours — signs that may indicate an allergic reaction or require clinical evaluation.
“Vaccination remains the most effective tool we have to prevent measles outbreaks and protect populations from yellow fever. In regions where immunity has waned, timely immunization campaigns like Colombia’s are not just beneficial — they are essential for maintaining public health security.”
“The safety and efficacy of the yellow fever 17D vaccine are well-established through decades of use. A single dose provides robust, long-term protection, and we continue to affirm its role as a cornerstone of preventive medicine in endemic countries.”
| Vaccine | Dose Schedule | |||
|---|---|---|---|---|
| Measles (MMR) | 2 doses (12–15 mo, 4–6 yr) | 2–3 weeks | Lifelong (after 2 doses) | Fever, rash, lymphadenopathy |
| Yellow Fever (17D) | 1 dose | 10 days (80–100%) 30 days (99%) |
≥30 years (likely lifelong) | Headache, myalgia, low-grade fever |
References
- World Health Organization. (2025). Measles outbreaks and global surveillance update. https://www.who.int/news-room/fact-sheets/detail/measles
- Pan American Health Organization. (2026). Yellow fever in the Americas: epidemiological update. https://www.paho.org/en/topics/yellow-fever
- CDC. (2024). Measles, Mumps, and Rubella (MMR) Vaccination: What Everyone Should Grasp. https://www.cdc.gov/vaccines/vpd/mmr/public/index.html
- Monath, T. P., et al. (2002). Yellow fever vaccine. In Plotkin SA, Orenstein WA, Offit PA (Eds.), Vaccines (5th ed.). Saunders. https://doi.org/10.1016/B0-12-657470-5/00084-1
- WHO. (2023). Immunization Agenda 2030: A Global Strategy to Leave No One Behind. https://www.who.int/teams/immunization-vaccines-and-biologicals/strategies/ia2030
